menu search

EPZM / Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why
Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang. Read More
Posted: Mar 16 2022, 13:32
Author Name: Zacks Investment Research
Views: 112226

EPZM News  

Why Epizyme Stock Is Soaring Today

By The Motley Fool
June 27, 2022

Why Epizyme Stock Is Soaring Today

A buyout ends Epizyme's 15-year tenure as an independent biopharma. more_horizontal

Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why

By Benzinga
June 27, 2022

Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why

Ipsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for approximately $247 million, plus one contingent valu more_horizontal

Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report?

By Zacks Investment Research
March 31, 2022

Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? more_horizontal

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

By Zacks Investment Research
March 16, 2022

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the more_horizontal

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

By Zacks Investment Research
March 2, 2022

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. more_horizontal

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

By Zacks Investment Research
March 2, 2022

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. more_horizontal

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

By Zacks Investment Research
March 2, 2022

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. more_horizontal


Search within

Pages Search Results: